Prosecution Insights
Last updated: April 19, 2026

Examiner: JEAN-LOUIS, SAMIRA JM

Tech Center 1600 • Art Units: 1617 1627 1642

This examiner grants 62% of resolved cases

Performance Statistics

61.7%
Allow Rate
+1.7% vs TC avg
977
Total Applications
+45.4%
Interview Lift
1061
Avg Prosecution Days
Based on 963 resolved cases, 2023–2026

Rejection Statute Breakdown

1.0%
§101 Eligibility
8.5%
§102 Novelty
36.8%
§103 Obviousness
29.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18576149 PREPARATION OF SUBSTITUTED AMIDOXIMES Non-Final OA BASF SE
18558423 TREATMENT OF PHARMACORESISTANT EPILEPSY Non-Final OA Katholieke Universiteit Leuven
18071724 COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT Non-Final OA Northwestern University
17895280 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MYELIN RELATED AND INFLAMMATION RELATED DISEASES OR DISORDERS Final Rejection Duke University
18250596 METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR Non-Final OA Arena Pharmaceuticals, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month